RSLS Stock Overview
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
ReShape Lifesciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.56|
|52 Week High||US$6.25|
|52 Week Low||US$0.55|
|1 Month Change||-40.72%|
|3 Month Change||-50.85%|
|1 Year Change||-87.79%|
|3 Year Change||-93.03%|
|5 Year Change||-100.00%|
|Change since IPO||-100.00%|
Recent News & Updates
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results
It's shaping up to be a tough period for ReShape Lifesciences Inc. ( NASDAQ:RSLS ), which a week ago released some...
|RSLS||US Medical Equipment||US Market|
Return vs Industry: RSLS underperformed the US Medical Equipment industry which returned -25.9% over the past year.
Return vs Market: RSLS underperformed the US Market which returned -21.7% over the past year.
|RSLS Average Weekly Movement||12.8%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RSLS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: RSLS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Fundamentals Summary
|RSLS fundamental statistics|
Is RSLS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RSLS income statement (TTM)|
|Cost of Revenue||US$5.54m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.49|
|Net Profit Margin||-509.20%|
How did RSLS perform over the long term?See historical performance and comparison
Is RSLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RSLS?
Other financial metrics that can be useful for relative valuation.
|What is RSLS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does RSLS's PS Ratio compare to its peers?
|RSLS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
GTHP Guided Therapeutics
SINT Sintx Technologies
HYBT Heyu Biological Technology
RSLS ReShape Lifesciences
Price-To-Sales vs Peers: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (68.2x).
Price to Earnings Ratio vs Industry
How does RSLS's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Medical Equipment industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is RSLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.8x|
|Fair PS Ratio||5.5x|
Price-To-Sales vs Fair Ratio: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (5.5x).
Share Price vs Fair Value
What is the Fair Price of RSLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RSLS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RSLS's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RSLS's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is ReShape Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RSLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RSLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RSLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RSLS's revenue (42.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: RSLS's revenue (42.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RSLS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has ReShape Lifesciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RSLS is currently unprofitable.
Growing Profit Margin: RSLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RSLS is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Accelerating Growth: Unable to compare RSLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RSLS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: RSLS has a negative Return on Equity (-168.99%), as it is currently unprofitable.
Discover strong past performing companies
How is ReShape Lifesciences's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RSLS's short term assets ($23.6M) exceed its short term liabilities ($8.2M).
Long Term Liabilities: RSLS's short term assets ($23.6M) exceed its long term liabilities ($494.0K).
Debt to Equity History and Analysis
Debt Level: RSLS is debt free.
Reducing Debt: RSLS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RSLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RSLS has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.
Discover healthy companies
What is ReShape Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RSLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RSLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RSLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RSLS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RSLS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bart Bandy (61 yo)
Mr. Barton P. Bandy, also known as Bart, has been the President and Chief Executive Officer of ReShape Lifesciences Inc. since April 1, 2019 and has been its Director since May 8, 2019. Mr. Bandy served as...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Bart's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Bart's compensation has been consistent with company performance over the past year.
Experienced Management: RSLS's management team is considered experienced (2.7 years average tenure).
Experienced Board: RSLS's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RSLS insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 135.8%.
ReShape Lifesciences Inc.'s employee growth, exchange listings and data sources
- Name: ReShape Lifesciences Inc.
- Ticker: RSLS
- Exchange: NasdaqCM
- Founded: 2002
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$10.474m
- Shares outstanding: 18.69m
- Website: https://www.reshapelifesciences.com
Number of Employees
- ReShape Lifesciences Inc.
- 1001 Calle Amanecer
- San Clemente
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.